Table 2.

Associations of Antidepressant Medication Types With Incident CVD in the ARIC Cohort (n=2027 Overall, Excluding Prevalent Cases in Each Analysis; n=81 AF; n=89 HF; n=84 MI; and n=62 Ischemic Stroke)

Outcomes
	AF	HF	MI	Ischemic Stroke
Number of events
Total	332	365	174	119
SSRI	136	137	62	43
Non‐SSRI	196	228	112	76
Median follow‐up, y	13.4	13.6	13.5	14.5

HR (95% CI) for SSRIs Compared With Non‐SSRIsa
Model 1b	1.10 (0.83–1.47)	0.95 (0.76–1.19)	0.81 (0.60–1.11)	0.85 (0.59–1.24)
Model 2c	1.10 (0.86–1.41)	0.98 (0.77–1.25)	0.91 (0.64–1.29)	1.07 (0.70–1.63)
Model 3d	1.11 (0.86–1.42)	1.03 (0.80–1.32)	0.88 (0.61–1.26)	1.12 (0.82–1.74)
Model 4e	1.07 (0.82–1.41)	1.05 (0.81– 1.36)	0.82 (0.56–1.19)	1.07 (0.70–1.63)
Model 5f	1.10 (0.85–1.40)	0.90 (0.70–1.17)	0.83 (0.61–1.15)	0.91 (0.62–1.35)

AF indicates atrial fibrillation; ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; CVD, cardiovascular disease; HDL, high‐density lipoprotein; HF, heart failure; HR, hazards ratio; LDL, low‐density lipoprotein; MI, myocardial infarction; SSRI, selective serotonin reuptake inhibitor.

^aHRs are for associations of using SSRIs compared with non‐SSRIs, with each outcome.

^bAdjusted for age, sex, race/center, and education.

^cAdditional adjustment for BMI, cigarette smoking, alcohol use, antihypertensive medications, diabetes mellitus, and the year of diagnosis (HDL, LDL, statins use for MI and stroke model).

^dAdditional adjustment for vital exhaustion questionnaire scores (quartiles).

^eAdditional adjustment for BMI, cigarette smoking, alcohol use, antihypertensive medications, diabetes mellitus (HDL, LDL, statins use for MI and stroke models), and the year of diagnosis while omitting visit 5.

^fFine and Gray model adjusted for BMI, cigarette smoking, alcohol use, antihypertensive medications, diabetes mellitus (HDL, LDL, statin use for MI and stroke models), and the year of diagnosis, while considering mortality as a competing risk.